Johns Hopkins troubles raise trial questions  by Bonetta, Laura
After a shutdown that lasted three
days, human research at Johns
Hopkins University has resumed
under severe restrictions imposed by
the US Office of Human Research
Protection (OHRP). The
disciplinary actions came after the
death in June of an otherwise
healthy volunteer who participated
in an asthma study. 
Meanwhile, the University of
California at San Francisco (UCSF)
will re-examine a 1978 study in
which two research volunteers
became sick after inhaling the same
drug that presumably led to the
death of the Johns Hopkins
volunteer, 24 year old Ellen Roche.
At the time of the UCSF study, lead
investigators did not report the
volunteers’ illnesses because they
did not believe they were linked to
the drug. “The committee on human
research is now looking at the study
to see if there is anything that we
can learn from it retrospectively. I do
not know how long that will take,”
says Alice Trinkl, spokesperson for
UCSF.
The drug used in both studies is
hexamethonium, which blocks a class
of receptors on sympathetic ganglion
neurons. The drug was used as a high
blood pressure medication in the
1950s and 1960s, but was taken off
the market in 1972. A number of
articles published in the 1950s
reported that the drug could induce
severe lung toxicity and even death
in some patients. 
Alkis Togias, lead investigator of
the study at Johns Hopkins, planned
to administer hexamethonium to
healthy volunteers to block certain
bronchial nerve ganglia and thereby
investigate the neuronal mechanisms
that protect the lungs of healthy
individuals from asthma attacks. A
university review committee that
investigated the study concluded
that volunteer Ellen Roche most
likely died from adult respiratory
distress syndrome as a result of
exposure to the drug. 
The committee criticised the
internal review board (IRB) that
approved the study for not requiring
more evidence of safety in the use of
hexamethonium (both Togias and
the IRB apparently failed to look up
the 1950s articles warning of lung
damage). According to the
committee’s report the consent form
signed by the research volunteers
was ‘inadequate in the description of
the research risks.’ In addition,
committee members said that
Dr. Togias should have promptly
reported to the IRB that a previous
volunteer in the study had
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developed a cough that lasted nine
days.
In the 1978 UCSF study that also
used hexamethonium, one of the
four volunteers complained of a
headache and vague discomfort and
was withdrawn from the study.
Another volunteer developed chest
tightness and shortness of breath
after the study ended. In both cases
the adverse reaction was not
attributed to hexamethonium use
and was not reported to review
boards or in the 1980 article
published in the American Review of
Respiratory Disease. According to Neal
Cohen, vice dean for academic affairs
at UCSF, “23 years ago we reported
events when we were aware that they
were associated with a study. Today it
is the standard to report all events
whether we believe they are
associated with a study or not.”
While federal regulators have
accepted Hopkins’ plans to improve
safeguards and lifted the suspension
of human medical research, they
have required that most of the 2,500
studies that were being conducted at
the institution be re-reviewed by the
IRBs and then approved by the
OHRP. 
“Priorities have been established
for re-reviews so that some studies
will be back in operation sooner and
others later,” says Joann Rodgers, a
spokesperson for Johns Hopkins
University. 
Johns Hopkins is the latest in a
number of highly publicized cases,
including Duke University and the
University of Pennsylvania, that have
resulted in suspensions of human
medical research and raised
questions about the efficacy of the
existing system for monitoring the
safety of research volunteers. “You
cannot fix the problem by pointing
fingers. It is a systems problem,” says
Philip Walson, director of clinical
trials at Children’s Hospital Medical
Center of Cincinnati. 
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